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Abstract
Background At current prognostication of low grade glioma remains suboptimal and might be improved with additional 
markers. These may guide treatment decisions, in particular on early adjuvant therapy versus wait and see after surgery.
Methods We used a targeted Next-Generation Sequencing panel to assess mutational and copy number status of selected 
genes and chromosomes in a consecutive series of adult grade II supratentorial glioma, and assessed the impact of molecular 
markers of interest on overall survival.
Results 207 IDH mutated grade II glioma samples were analyzed with a median follow-up of 6.9 years. Loss of region 
9p21.3 did not show a correlation with outcome in IDH mutated 1p/19q-codeleted oligodendroglioma or IDH mutated 
astrocytoma. We found a significant shorter overall survival with univariable analysis in IDH mutated astrocytoma patients 
with trisomy of chromosome 7 (Log rank P = 0.044) and in IDH mutated 1p/19q-codeleted oligodendroglioma patients with 
a PTEN mutation (Log rank P = 0.033). We could not validate these findings in multivariate analysis or in the TCGA dataset.
Conclusions Loss of 9p21.3 is not associated with outcome in a molecularly defined cohort of grade II glioma and therefore 
it remains unclear if loss of 9p21.3 can be used as additional marker of anaplasia or to guide treatment decisions. Trisomy of 
chromosome 7 in IDH mutated astrocytoma and PTEN mutations in IDH mutated oligodendroglioma are potential markers 
of poor prognosis, but require confirmation in larger series.
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Introduction
In 2016 the World Health Organization Classification of 
Tumors of the Central Nervous System (WHO) was updated, 
resulting in a major change in the classification of diffuse 
gliomas [1]. The 2016 WHO classification provides an inte-
grated diagnosis of glioma by combining histopathological 
with genotypic features. Moreover, in the case of discrep-
ancy between genotypic and histopathological features, the 
genotypic features are leading in classifying a glioma sub-
type. As a result the 2016 CNS WHO markedly improved 
the objectivity of classification and prognosis estimation as 
compared to the previous version [1–3].
Three clinically relevant subgroups of diffuse low-grade 
(grade II) gliomas are identified and recognized by the WHO 
2016 classification based on two molecular markers: (1) oli-
godendroglioma, IDH mutant and 1p/19q-codeleted (IDH1/2 
mutation in combination with presence of a co-deletion of 
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the entire 1p and 19q chromosomal arms), (2) diffuse astro-
cytoma, IDH mutant; (IDH1/2 mutation without 1p19q co-
deletion), and (3) diffuse astrocytoma, IDH1/2 wildtype. 
Other frequently reported genetic changes in glioma are 
CIC, FUBP1, TP53, ATRX, TERT promoter mutations and 
copy number changes of chromosome 7, 9, and 10 [1, 2, 
4, 5]. Although the 2016 CNS WHO update is robust and 
provides a more accurate prognosis estimation, there is still 
variation in outcome within the different entities and the 
grading of glioma is still depending on histological features. 
Prognostication might be further improved if additional 
molecular markers can be identified that correlate with prog-
nosis. These markers may facilitate treatment decisions, in 
particular for early radiotherapy and adjuvant chemotherapy 
versus a wait and watch policy after surgery. This is in par-
ticular relevant, as the currently used criteria (age of 40, less 
than gross total resection) are quite arbitrary, and in some 
patients that are 40 years or older with a less than gross total 
resection, a wait and watch period of years is possible [6–8]. 
Thus, molecular factors showing a clinically significant rela-
tion with outcome would be highly welcome.
Several studies have tried to further stratify molecularly 
defined glioma, most of them in anaplastic glioma. For 
example, some studies showed that loss of chromosome 9p 
or specifically the 9p21.3 region is associated with a worse 
prognosis in various subtypes of grade III and IV glioma 
[9–11]. This could however not be validated in a recently 
published large cohort of grade II and III glioma [12]. In 
the present study we aimed to identify molecular prognostic 
markers for grade II IDH mutated astrocytoma (in particular 
loss of 10q, trisomy of chromosome 7, PTEN mutations) 
and in grade II IDH mutated 1p19q-codeleted oligodendro-
glioma (in particular loss of 9p21.3, CIC, FUBP1, and PTEN 
mutations). To our knowledge there are no published studies 
that investigated prognostic impact of these markers specifi-
cally in molecularly defined grade II glioma. Therefore, in a 
well-defined cohort of histologically proven supratentorial 
adult grade II glioma we used a targeted Next-Generation 
Sequencing panel for molecular classification and evaluated 
the prognostic value of glioma specific molecular markers.
Methods
Patient selection
For this study we used a cohort of patients from a pro-
ject on extent of resection in grade II glioma [13]. Adult 
patients (age ≥ 18 years) with histopathologically confirmed 
supratentorial grade II glioma were included. Tissue samples 
were collected in two Dutch hospitals (Erasmus MC Cancer 
Institute, Rotterdam; and Elisabeth-TweeSteden Hospital, 
Tilburg). Histopathological diagnosis and low grade was 
confirmed by a dedicated neuropathologist (J.M.K.). Time-
window of patient inclusion was 2003–2016. For clinical 
factors, age, KPS, type of surgery, and treatment after sur-
gery were collected. This study was approved by the medical 
ethics committee of Erasmus MC.
DNA extraction
DNA was isolated from formalin-fixed-paraffin-embedded 
(FFPE) tissue blocks. Tissue areas with high percentage of 
neoplastic cells (preferably > 70%, but at least 50%) were 
manually macrodissected from 10 µm sections. Macrodis-
sected tissue was digested using Proteinase K incubation at 
56 °C overnight in presence of 5% Chelex 100 resin (Bio-
Rad). After overnight incubation, proteinase K was inacti-
vated at 90 °C for 10 min. Next, dissolved DNA was sepa-
rated from Chelex resin and cell debris by centrifugation at 
20 g for 5 min. DNA concentration was measured using the 
Qubit 3.0 Fluorometer according to manufacturer’s protocol 
(Life Technologies).
Next‑Generation‑Sequencing
We used Next-Generation Sequencing to assess mutational 
and copy number status of selected genes and chromosomes. 
The primer panel consisted of primers for glioma specific 
genes of interest (hot spot regions, or whole gene) and prim-
ers for highly polymorphic single nucleotide polymorphisms 
to detect large genomic alterations in chromosomes of inter-
est. Chromosomal imbalances and loss of heterozygosity 
(LOH) were estimated as described previously [3]. An over-
view of the targeted hotspots/whole genes and chromosomes 
is shown in Supplementary Table 1. Sequencing was per-
formed with the Ion Torrent Personal Genome Machine or 
Ion S5 (Life Technologies). TERT promoter mutational sta-
tus (C228T and C250T mutation) was assessed in a separate 
assay as described before (SNaPshot, Life Technologies) [3].
Survival
All patients were followed until death or censored at date 
of last follow-up. Overall survival (OS) was measured from 
the date of diagnostic scan until date of death or censor-
ship. Date of death was provided by patient records or the 
Municipal Personal Records Database. The database was 
developed and maintained at Erasmus MC, and locked on 
March 21st 2018.
Statistical analysis
All analyses were performed using R (3.3.2) and RStudio 
(1.0.44). Overall survival was measured as time between 
date of diagnostic scan and date of death or censorship. 
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Overall survival is shown in Kaplan–Meier plots (ggplot2 
package in R). Univariable analyses were performed using 
the Log-rank test and multivariable analyses with Cox 
proportional-hazards models. Categorical data were ana-
lyzed with Pearson’s Chi square test or Fisher’s exact test 
when assumptions of the Chi square test were violated (as 
indicated in the respective tables). Kruskal–Wallis test 
was used for continuous data. All calculations were two-
sided tests, with a P value < 0.05 considered as statistically 
significant.
Results
We identified 246 patients with a pathologically confirmed 
grade II glioma with available FFPE material. Of these, 2 
patients were excluded due to insufficient DNA yield and no 
remaining tissue for DNA isolation, and 14 were excluded 
from analysis due to sequencing failure (very low coverage 
and/or uniformity for most amplicons after two attempts). 
At the time of analysis, 53 patients were reported dead, 
15 of the 95 IDH mutated 1p/19q-codeleted oligodendro-
glioma patients and 38 of the 112 IDH mutated astrocytoma 
patients.
Molecular classification
As we were interested in additional markers for IDH mutated 
grade II glioma, 23 patient samples that were classified as 
IDH wildtype were excluded from further analyses. 207 
patients were included in final analyses with a median fol-
low-up of 6.9 years (range 0.4–21.7 years). Clinical char-
acteristics are shown in Table 1. An oncoprint plot with all 
mutations and copy number alterations for the 207 patients 
is shown in Fig. 1. Mutation frequencies per molecular sub-
group are shown in Table 2. Median overall survival per 
CNS WHO 2016 molecular subgroup was consistent with 
literature (Supplementary Fig. 1).
IDH mutated astrocytoma
107 of the 112 IDH mutated astrocytomas could be reli-
ably evaluated for imbalance of chromosome 7: 13 samples 
showed imbalance compatible with trisomy of the entire 
chromosome 7. In univariable analysis trisomy of chromo-
some 7 was significantly associated with shorter overall sur-
vival (Log rank P = 0.044). However, this survival difference 
lost significance when correcting for age and KPS (HR 2.22; 
95% CI 0.95–5.20; P = 0.066). Only two samples showed 
loss of entire chromosomal arm 10q, both with a relatively 
poor overall survival of less than 8 years (Fig. 2). Loss of 
9p21.3 (n = 18) was not associated with outcome. Out of 
the 18 patients with loss of 9p21.3, 13 showed loss of the 
entire 9p chromosomal arm, which was also not associated 
with outcome. A PTEN mutation was detected in 3 patients 
(all three no loss of 10q) and did not show an impact on 
outcome (Fig. 2).
IDH mutated 1p/19q‑codeleted oligodendroglioma
In IDH mutated 1p/19q-codeleted oligodendroglioma, both 
CIC and FUBP1 mutations were frequent events, but nei-
ther was associated with prognosis (Fig. 3). In 27 out of the 
77 patients that could be reliably evaluated for copy num-
ber changes on chromosome 9p, loss of 9p21.3 was found. 
Of these, 23 showed loss of entire chromosomal arm 9p. 
No homozygous deletions or mutations of CDKN2A were 
detected. Loss of 9p21.3 did not have significant impact 
on overall survival (Log rank P = 0.12) (Fig. 3). Additional 
analysis for impact of loss of entire 9p did not show differ-
ent results. Trisomy of chromosome 7 and loss of chromo-
somal arm 10q were present in a few samples, both without 
Table 1  Patient characteristics
† Fisher’s exact test
Characteristics Oligodendro-
glioma
Astrocytoma 
IDHmt
P
N % N %
Patients (n) 95 112
Sex 0.149
 Male 49 51.6 71 63.4
 Female 46 48.4 41 36.6
Age < 0.0001
 Median (IQR) 45 (37–52) 37 (29–45)
Type of 1st surgery 0.002†
 Awake craniotomy 51 53.7 54 48.2
 Normal resection 23 24.2 49 43.8
 Open biopsy 7 7.4 2 1.8
 Stereotactic biopsy 14 14.7 7 6.2
Preoperative KPS 0.064
 Median (IQR) 100 (100–100) 100 (90–100)
Histopathological diagnosis
 Grade II astrocytoma 8 8.4 87 77.7
 Grade II oligodendro-
glioma
77 81.1 9 8.0
 Grade II oligo-astro-
cytoma
10 10.5 16 14.3
Treatment after 1st 
surgery
< 0.0001
 Wait and scan 52 54.7 52 46.4
 Chemotherapy 24 25.3 5 4.5
 Radiotherapy 16 16.8 42 37.5
 Chemoradiation 3 3.2 13 11.6
Follow-up (years)
 Median (range) 8.0 (0.9–21.7) 6.1 (0.4–16.7)
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impact on overall survival (Fig. 3). Five patients were PTEN 
mutated and showed a significantly shorter OS in univariable 
analysis (Log rank P = 0.033). This survival difference was 
not significant anymore when correcting for age and KPS 
(HR 3.73; 95% CI 0.78–17.76; P = 0.097).
Exploratory analyses
On further exploratory analyses, we found no other molecu-
lar markers that significantly impact on overall survival in 
molecularly defined LGG with the targeted sequencing panel 
we used.
Validation of findings in the TCGA 
We aimed to validate our findings in the publically avail-
able dataset The Cancer Genome Atlas (TCGA). In the 
TCGA dataset, 9 out of 72 grade II IDH mutated astrocy-
toma showed trisomy of chromosome 7, but this was not 
significantly associated with a difference in overall survival 
in univariate analysis (Log rank P = 0.3). We also analyzed 
the TCGA dataset for presence of loss of 10q in grade II IDH 
mutated astrocytoma. Only one sample showed loss of 10q, 
with a poor survival (1.75 years). Among the 47 grade II 
IDH mutated 1p/19q-codeleted oligodendroglioma samples 
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Fig. 1  Oncoprint plot with overview of somatic alterations per 
patient. At the top of the figure the WHO 2007 and WHO 2016 clas-
sification are shown. In the middle part all somatic variants and copy 
number alterations are shown. Patients are separated based on the 
WHO 2016 classification. IDH mutated 1p/19q-codeleted patients are 
depicted in the left part of the figure and IDH mutated astrocytoma 
patients on the right part of the figure. The bottom part of the figure 
shows the clinical characteristic age per patient
Table 2  Frequencies of gene mutations per WHO subgroup
Gene IDH mutated astrocytoma IDH mutated 
1p/19q-codeleted 
oligodendro-
glioma
N % N %
IDH1 111 99.1 87 91.6
IDH2 1 0.9 8 8.4
TP53 105 93.8 0 0
ATRX 75 67 0 0
CIC 2 1.8 52 54.7
FUBP1 0 0 36 37.9
TERT 3 2.7 91 95.8
PIK3CA 1 0.9 2 2.1
EGFR 0 0 0 0
NOTCH1 3 2.7 3 3.2
PTEN 3 2.7 5 5.3
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in the TCGA dataset, there were no samples with a PTEN 
mutation, confirming the rarity of this event.
Discussion
In this study we aimed to investigate the prognostic impact 
of additional molecular markers in grade II IDH mutated 
astrocytoma and grade II IDH mutated 1p/19q-codeleted 
oligodendroglioma. We used a targeted NGS panel to inves-
tigate genes that are frequently mutated in glioma and to 
investigate regions that are frequently reported to have copy 
number changes.
Loss of chromosome 9p or in particular the 9p21.3 
region is a frequently reported copy number variation 
in all glioma subtypes [2, 9–11]. Several studies inves-
tigated the impact of loss of 9p/9p21.3 on prognosis. A 
meta-analysis published in 2015 pooled the data of 13 
different studies that were published between 2002 and 
2013 [10]. Although most individual studies in this meta-
analysis did not show a survival difference, the pooled 
data showed that loss of 9p was significantly associated 
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Fig. 2  Kaplan–Meier plots with overall survival of IDH mutated 
astrocytoma patients. Kaplan–Meier plots with overall survival of 
IDH mutated astrocytoma patients stratified for presence of a imbal-
ance pattern consistent with trisomy of chromosome 7, b loss of 
9p21.3 region, c loss of chromosomal arm 10q, d and presence of a 
PTEN mutation
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with a poorer prognosis. However, most studies in this 
analysis did not take into account confounding factors such 
as IDH1/2 mutational status, and a subgroup analysis of 
types of gliomas showed that impact of loss of 9p on over-
all survival was particularly present in the glioblastoma 
subtype. A recent study specifically focused on the impact 
of 9p loss in grade II and III glioma and found that loss 
of 9p is an independent prognostic factor in IDH mutated 
glioma, however, the effect was most clear in IDH mutated 
astrocytomas [11]. In opposite, Alentorn et al. found loss 
of 9p to be a poor prognostic marker in anaplastic oli-
godendroglioma [9]. A later study by Aoki et al. did not 
confirm this finding however [12]. Our study is the first 
that specifically focusses on the impact of loss of 9p21.3 
and entire 9p in histologically defined grade II glioma. We 
could not confirm impact of loss of 9p21.3 region or entire 
9p on prognosis in IDH mutated astrocytoma nor in IDH 
mutated 1p/19q-codeleted oligodendroglioma. However, 
a trend towards shorter overall survival in IDH mutated 
1p/19q-codeleted oligodendroglioma with loss of 9p21.3 
is visible, and longer follow-up and larger sample size is 
necessary for final conclusions. Exact comparison of our 
data with previous literature is difficult, because of differ-
ent selection criteria in the different cohorts. Therefore, 
it is yet unclear if in grade II IDH mutated glioma loss 
of 9p21.3 region can be used as marker of anaplasia or to 
guide more aggressive treatment strategies.
Trisomy of chromosome 7 is also frequently reported 
in glioma [2, 14, 15]. In combination with loss of 10q it 
is considered an early event in glioblastoma IDH wildtype 
and is correlated with dismal prognosis in grade II and III 
IDH wildtype glioma [2, 15–17]. Trisomy of chromosome 
7 is also described in lower grade glioma, though less fre-
quently. The impact of trisomy of 7 on overall survival in 
IDH mutated low grade glioma is not clear. To our knowl-
edge no large series are published. Wessels et al. reported 
that polysomy of 7 was associated with a poorer prognosis in 
grade II astrocytoma, but this report antedates the discovery 
of the role IDH mutations in glioma [14]. In our cohort we 
found that trisomy of chromosome 7 might be a marker of 
poor prognosis in IDH mutated astrocytoma. However, this 
could not be validated in multivariate analysis nor in the 
TCGA data, and this observation requires validation in a 
larger independent cohort to define the clinical value.
CIC and FUBP1 mutations are frequently mutated in 
IDH mutated 1p/19q-codeleted oligodendroglioma and the 
prognostic impact has been investigated in several series. 
One study by Gleize et al. reported that inactivating CIC 
mutations in IDH mutated glioma correlate with poorer 
outcome. In other cohorts this effect was not observed [3, 
18–20]. In our cohort we also did not find a correlation 
between CIC nor FUBP1 mutation and prognosis.
Our study has several limitations. The retrospective 
nature comes with the risk of a selection bias. We tried 
to avoid selection bias by analyzing a consecutive cohort 
of all grade II gliomas undergoing surgery within a speci-
fied period. Also due to the retrospective nature, treatment 
was heterogeneous. Furthermore, we may have missed 
smaller region copy number alterations and other muta-
tions in regions not covered by our NGS panel. We used 
a diagnostically validated [21] and targeted NGS panel 
that consists of highly polymorphic SNPs that cover whole 
chromosomes of interest with roughly 1 SNP per 3 MB. 
Large scale copy number variations of whole chromo-
somes or large parts of chromosomes can therefore be reli-
ably detected, but small region or subclonal copy number 
variations are potentially missed. However, the aim of 
this study was to validate the impact of large region copy 
number variations which were described before and that 
are considered to be early events, and these can be reli-
ably detected with the panel used [21]. Also, it is known 
that lengthy follow-up in studies on low-grade glioma is 
necessary for definitive conclusions, so longer of follow 
up of this dataset is necessary.
In conclusion, in univariable analysis we found a sig-
nificant shorter overall survival in IDH mutated astrocy-
toma patients with trisomy of chromosome 7, and in IDH 
mutated 1p/19q-codeleted oligodendroglioma patients 
with a PTEN mutation. However, we could not confirm 
these findings in multivariate analysis or in the TCGA 
validation set and therefore these findings require valida-
tion in other larger series. We could not confirm the impact 
on OS of LOH of 9p21.3 (the CDKN2A region) which is 
frequently reported as a progression marker particularly in 
higher grade glioma. However, we need lengthy follow-up 
for definitive conclusions. Also, other strategies should 
be pursued to identify prognostic relevant molecular 
markers within these IDH mutant glioma subgroups, like 
methylation patterns and total number of chromosomal 
aberrations.
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